SG Americas Securities LLC lifted its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 31.1% in the fourth quarter, according to the company in its most recent filing with ...

A simple conversation with Megan McCabe about her research is enough to see she is a scientist in the making. The recent ...

DelveInsight’s c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline ...

Nurix Therapeutics (NRIX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jeet ...

J.P. Morgan analyst Eric Joseph maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report) today and set a price target of $30.00.

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next ...

Nuvalent, Inc. is a Cambridge, Massachusetts based clinical-stage biopharmaceutical concern focused on the development of precision medicines to treat cancer. The company is advancing three ...

Nurix's wholly owned, clinical stage pipeline includes degraders of Bruton's tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), ...

Panel A summarizes the conventional model of how oncogenic RAS guanosine triphosphatases (i.e., Kirsten rat sarcoma viral oncogene homologue [KRAS], neuroblastoma RAS viral oncogene homologue ...

These modifications increase chromatin accessibility, influencing growth, differentiation, and ion transport, with contrasting effects on normal and colorectal cancer cells. Study: Short-chain ...

These SCFAs can influence the activity of both cancer-promoting (proto-oncogenes) and cancer-suppressing (tumor-suppressor) genes by modifying histones, the proteins that help package DNA.